Cargando…
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
Non-alcoholic fatty liver disease (NAFLD) comprises a heterogeneous group of metabolic liver diseases and is characterized by the presence of steatosis in at least 5% of hepatocytes. The aim of our study was to assess the effect of the combination therapy of empagliflozin + metformin vs. metformin m...
Autores principales: | Caturano, Alfredo, Galiero, Raffaele, Loffredo, Giuseppe, Vetrano, Erica, Medicamento, Giulia, Acierno, Carlo, Rinaldi, Luca, Marrone, Aldo, Salvatore, Teresa, Monda, Marcellino, Sardu, Celestino, Marfella, Raffaele, Sasso, Ferdinando Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952909/ https://www.ncbi.nlm.nih.gov/pubmed/36830859 http://dx.doi.org/10.3390/biomedicines11020322 |
Ejemplares similares
-
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations
por: Galiero, Raffaele, et al.
Publicado: (2023) -
Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence
por: Salvatore, Teresa, et al.
Publicado: (2021) -
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes
por: Salvatore, Teresa, et al.
Publicado: (2022) -
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
por: Salvatore, Teresa, et al.
Publicado: (2021) -
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies
por: Vetrano, Erica, et al.
Publicado: (2023)